vspВопросы современной педиатрииCurrent Pediatrics1682-55271682-5535Издательство «ПедиатрЪ»vsp-629Research ArticleКЛИНИЧЕСКИЕ НАБЛЮДЕНИЯCLINICAL OBSERVATIONSЧеловеческие моноклональные антитела к ФНО : новые возможности в лечении ювенильного идиопатического артритаHUMAN MONOCLONAL ANTIBODIES TO TNF: NEW OPPORTUNITIES IN TREATMENT OF JUVENILE IDIOPATHIC SPONDYLITISДенисоваР.В.DenisovaR.V.denisovarv@yandex.ruАлексееваЕ.И.AlekseevaE.I.neonatepearl@yandex.ruНаучный центр здоровья детей РАМН, МоскваSсientific Center of Children’s Health, Russian Academy of Medical Sciences, MoscowНаучный центр здоровья детей РАМН, Москва
Первый Московский государственный медицинский университет им. И.М. СеченоваSсientific Center of Children’s Health, Russian Academy of Medical Sciences, Moscow
I.M. Sechenov First Moscow State Medical University201116052011103Вопросы современной педиатрии150–156Copyright © Денисова Р., Алексеева Е., 20112011Денисова Р., Алексеева Е.Denisova R., Alekseeva E.This work is licensed under a Creative Commons Attribution 4.0 License.https://vsp.spr-journal.ru/jour/article/view/629ReferencesCassidy J., Petty R. Texbook of paediatric rheumatology. 5 еd. Philadelphia: Elsevier Saunders. 2005.Cassidy J., Petty R. Texbook of paediatric rheumatology. 5 еd. Philadelphia: Elsevier Saunders. 2005.Алексеева Е.И., Григорьева А.А., Денисова Р.В. Причины развития резистентности к ингибиторам ФНО α и пути ее преодоления. Вопросы современной педиатрии. 2009; 8 (6): 42–47.Алексеева Е.И., Григорьева А.А., Денисова Р.В. Причины развития резистентности к ингибиторам ФНО α и пути ее преодоления. Вопросы современной педиатрии. 2009; 8 (6): 42–47.Алексеева Е.И., Лисицин А.О., Карагулян Н.А. Адалимумаб: новые возможности лечения ювенильных артритов. Вопросы современной педиатрии. 2009; 8 (3): 88–94.Алексеева Е.И., Лисицин А.О., Карагулян Н.А. Адалимумаб: новые возможности лечения ювенильных артритов. Вопросы современной педиатрии. 2009; 8 (3): 88–94.Van der Heijde D., Kivitz A., Schiff M.H. et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis. Arthritis Rheum. 2006; 54 (7): 2136–2146.Van der Heijde D., Kivitz A., Schiff M.H. et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis. Arthritis Rheum. 2006; 54 (7): 2136–2146.Davis J.C., Revicki D., van der Heijde D.M. et al. Health-related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: results from a randomized controlled study. Arthritis Rheum. 2007; 57: 1050–1057.Davis J.C., Revicki D., van der Heijde D.M. et al. Health-related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: results from a randomized controlled study. Arthritis Rheum. 2007; 57: 1050–1057.Revicki D.A., Luo M.P. et al. Adalimumab reduces pain, fatigue, and stiffness in patients with ankylosing spondylitis: results from the adalimumab trial evaluating long-term safety and efficacy for ankylosing spondylitis (ATLAS). J. Rheumatol. 2008; 35 (7): 1346–1353.Revicki D.A., Luo M.P. et al. Adalimumab reduces pain, fatigue, and stiffness in patients with ankylosing spondylitis: results from the adalimumab trial evaluating long-term safety and efficacy for ankylosing spondylitis (ATLAS). J. Rheumatol. 2008; 35 (7): 1346–1353.Van der Heijde D., Schiff M.H., Sieper J. et al. Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial. Ann. Rheum. Dis. 2009; 68 (6): 922–929.Van der Heijde D., Schiff M.H., Sieper J. et al. Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial. Ann. Rheum. Dis. 2009; 68 (6): 922–929.Lambert R.G., Salonen D. et al. Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis: a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2007; 56 (12): 4005–4014.Lambert R.G., Salonen D. et al. Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis: a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2007; 56 (12): 4005–4014.Van der Heijde D., Pangan A.L., Schiff M.H. Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis. Ann. Rheum. Dis. 2008; 67 (9): 1218–1221.Van der Heijde D., Pangan A.L., Schiff M.H. Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis. Ann. Rheum. Dis. 2008; 67 (9): 1218–1221.Rudwaleit M., Claudepierre P., Kron M. et al. Effectiveness of adalimumab in treating patients with ankylosing spondylitis associated with enthesitis and peripheral arthritis. Arthritis Res. Ther. 2010; 12 (2): 43.Rudwaleit M., Claudepierre P., Kron M. et al. Effectiveness of adalimumab in treating patients with ankylosing spondylitis associated with enthesitis and peripheral arthritis. Arthritis Res. Ther. 2010; 12 (2): 43.Van der Heijde D., Salonen D., Weissman B.N., Landewé R. et al. Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Res. Ther. 2009; 11 (4): 127.Van der Heijde D., Salonen D., Weissman B.N., Landewé R. et al. Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Res. Ther. 2009; 11 (4): 127.Van der Heijde D.M., Revicki D.A. et al. Physical function, disease activity, and health-related quality of life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis. Arthritis Res. Ther. 2009; 11 (4): 124.Van der Heijde D.M., Revicki D.A. et al. Physical function, disease activity, and health-related quality of life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis. Arthritis Res. Ther. 2009; 11 (4): 124.Rudwaleit M., Claudepierre P.J. et al. Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis. Rheumatol. 2009; 36 (4): 801–808.Rudwaleit M., Claudepierre P.J. et al. Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis. Rheumatol. 2009; 36 (4): 801–808.Rudwaleit M., Olivieri I., Boki K.A. Adalimumab is effective and well tolerated in treating patients with ankylosing spondylitis who have advanced spinal fusion. Rheumatology (Oxford). 2009; 48 (5): 551–557.Rudwaleit M., Olivieri I., Boki K.A. Adalimumab is effective and well tolerated in treating patients with ankylosing spondylitis who have advanced spinal fusion. Rheumatology (Oxford). 2009; 48 (5): 551–557.Sulpice M., Deslandre C.J., Quartier P. Efficacy and safety of TNF alpha antagonist therapy in patients with juvenile spondyloarthropathies. Joint Bone Spine. 2009; 76 (1): 24–27.Sulpice M., Deslandre C.J., Quartier P. Efficacy and safety of TNF alpha antagonist therapy in patients with juvenile spondyloarthropathies. Joint Bone Spine. 2009; 76 (1): 24–27.
The authors declare that there are no conflicts of interest present.